Literature DB >> 20499280

Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma.

Fushi Wen1, Alex Shen, Reneé Shanas, Achyut Bhattacharyya, Fangru Lian, Galen Hostetter, Jiaqi Shi.   

Abstract

BACKGROUND: The heterogeneous nuclear ribonucleoprotein (hnRNP) K is an essential RNA and DNA binding protein involved in gene expression and signal transduction. The role of hnRNP K in cancer is relatively understudied. However, several cellular functions strongly indicate that hnRNP K is involved in tumorigenesis. Oncogenes c-Src, c-myc, and eIF4E are regulated by hnRNP K. We have shown an increased cytoplasmic hnRNP K in pancreatic cancer. In the present study, we investigated the altered expression of hnRNP K protein and its correlation with p-ERK in melanoma using human melanoma cell lines and tissue microarray.
MATERIALS AND METHODS: The protein levels of hnRNP K and p-ERK in 8 human melanoma cell lines and a melanoma progression tissue microarray containing 80 melanoma, 23 dysplastic nevi, and 14 benign nevi specimens were analyzed using Western blot and immunohistochemistry analysis. hnRNP K was knocked down by siRNA, and its effect on melanoma cells was assessed.
RESULTS: We showed a higher hnRNP K protein level in both melanoma cell lines and melanoma tissue specimens, which correlated with a higher c-myc expression. An increase in the cytoplasmic hnRNP K and eIF4E protein levels in melanoma cells is also seen. p-ERK level was also higher in dysplastic nevi and melanoma tissues, but did not correlate with hnRNP K protein level. We then demonstrated that knocking down of hnRNP K by siRNA inhibited melanoma cell growth and colony formation, as well as c-myc expression.
CONCLUSIONS: hnRNP K expression correlated with melanoma and may play a role in melanoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20499280      PMCID: PMC2943057          DOI: 10.1245/s10434-010-1121-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Characterization of hnRNP K protein-RNA interactions.

Authors:  Karolina Klimek-Tomczak; Lucjan S Wyrwicz; Sanjeev Jain; Karol Bomsztyk; Jerzy Ostrowski
Journal:  J Mol Biol       Date:  2004-09-24       Impact factor: 5.469

2.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Authors:  Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

3.  Genetics and genomics of melanoma.

Authors:  Papia Ghosh; Lynda Chin
Journal:  Expert Rev Dermatol       Date:  2009-04-01

4.  Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells.

Authors:  J Shi; A Kahle; J W B Hershey; B M Honchak; J A Warneke; S P L Leong; M A Nelson
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 5.  Poly(C)-binding proteins as transcriptional regulators of gene expression.

Authors:  Hack Sun Choi; Cheol Kyu Hwang; Kyu Young Song; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Biochem Biophys Res Commun       Date:  2009-01-27       Impact factor: 3.575

6.  Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.

Authors:  Irene Pino; Rubén Pío; Gemma Toledo; Natalia Zabalegui; Silvestre Vicent; Natalia Rey; María D Lozano; Wenceslao Torre; Jesús García-Foncillas; Luis M Montuenga
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

7.  Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro.

Authors:  M Takimoto; T Tomonaga; M Matunis; M Avigan; H Krutzsch; G Dreyfuss; D Levens
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

8.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

9.  Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.

Authors:  Kohji Nagano; John R Masters; Akunna Akpan; Alice Yang; Steve Corless; Chris Wood; Claire Hastie; Marketa Zvelebil; Rainer Cramer; Soren Naaby-Hansen
Journal:  Oncogene       Date:  2004-03-04       Impact factor: 9.867

10.  Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation.

Authors:  J Ostrowski; K Bomsztyk
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  20 in total

1.  Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.

Authors:  Luisa F Escobar-Hoyos; Alex Penson; Ram Kannan; Hana Cho; Chun-Hao Pan; Rohit K Singh; Lisa H Apken; G Aaron Hobbs; Renhe Luo; Nicolas Lecomte; Sruthi Babu; Fong Cheng Pan; Direna Alonso-Curbelo; John P Morris; Gokce Askan; Olivera Grbovic-Huezo; Paul Ogrodowski; Jonathan Bermeo; Joseph Saglimbeni; Cristian D Cruz; Yu-Jui Ho; Sharon A Lawrence; Jerry P Melchor; Grant A Goda; Karen Bai; Alessandro Pastore; Simon J Hogg; Srivatsan Raghavan; Peter Bailey; David K Chang; Andrew Biankin; Kenneth R Shroyer; Brian M Wolpin; Andrew J Aguirre; Andrea Ventura; Barry Taylor; Channing J Der; Daniel Dominguez; Daniel Kümmel; Andrea Oeckinghaus; Scott W Lowe; Robert K Bradley; Omar Abdel-Wahab; Steven D Leach
Journal:  Cancer Cell       Date:  2020-06-18       Impact factor: 31.743

2.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

3.  Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.

Authors:  Miguel Gallardo; Prerna Malaney; Marisa J L Aitken; Xiaorui Zhang; Todd M Link; Vrutant Shah; Sanzhar Alybayev; Meng-Han Wu; Laura R Pageon; Huaxian Ma; Rodrigo Jacamo; Li Yu; Zijun Y Xu-Monette; Haley Steinman; Hun Ju Lee; Dos Sarbassov; Inmaculada Rapado; Michelle C Barton; Joaquin Martinez-Lopez; Carlos Bueso-Ramos; Ken H Young; Sean M Post
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

4.  Lipoteichoic acid isolated from Lactobacillus plantarum inhibits melanogenesis in B16F10 mouse melanoma cells.

Authors:  Hye Rim Kim; Hangeun Kim; Bong Jun Jung; Ga Eun You; Soojin Jang; Dae Kyun Chung
Journal:  Mol Cells       Date:  2015-01-15       Impact factor: 5.034

5.  Transcriptional regulation of heterogeneous nuclear ribonucleoprotein K gene expression.

Authors:  Liqing He; Xiaochang Xue; Zhengjun Wang; Entai Hou; Yong Liu; Mingyu Liang; Yingqi Zhang; Zhongmin Tian
Journal:  Biochimie       Date:  2014-12-10       Impact factor: 4.079

6.  Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis.

Authors:  Ran Gao; Yue Yu; Atsushi Inoue; Nashi Widodo; Sunil C Kaul; Renu Wadhwa
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

7.  Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression.

Authors:  Christine E Kaiser; Natalie A Van Ert; Prashansa Agrawal; Reena Chawla; Danzhou Yang; Laurence H Hurley
Journal:  J Am Chem Soc       Date:  2017-06-15       Impact factor: 15.419

Review 8.  Aberrant hnRNP K expression: All roads lead to cancer.

Authors:  Miguel Gallardo; Marisa J Hornbaker; Xiaorui Zhang; Peter Hu; Carlos Bueso-Ramos; Sean M Post
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

Review 9.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

10.  The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation.

Authors:  Fushi Wen; Renyuan Zhou; Alex Shen; Andrew Choi; Diana Uribe; Jiaqi Shi
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.